Legacy Devices Under the MDR: What the 2027 and 2028 Deadlines Actually Require

Regulation (EU) 2023/607 gave many devices certified under the old directives extra time to move to the MDR, but the extension is conditional. A device that no longer meets those conditions loses its place in the transition, whatever date appears on its certificate.

The deadlines by risk class

  • Class III devices, and implantable class IIb devices (with the listed exceptions such as sutures, staples, screws and plates): until 31 December 2027.
  • Other class IIb devices, class IIa devices, and class I devices that are sterile or have a measuring function: until 31 December 2028.
  • Former class I devices that are now in a higher class under the MDR: also until 31 December 2028.

The conditions that keep the extension alive

The extension is not automatic. As summarised in published analyses of the Regulation, the manufacturer must be able to show that:

  • the device continues to comply with the Medical Device Directive or the Active Implantable Medical Devices Directive;
  • there are no significant changes in design or intended purpose;
  • the device does not present an unacceptable risk to health or safety;
  • a quality management system meeting Article 10(9) MDR was in place by 26 May 2024; and
  • a formal application was lodged with a notified body by 26 May 2024, with a written agreement signed by 26 September 2024.

Those dates have passed, so the practical question today is evidential: can you produce the application, the written agreement and the QMS records if an authority or notified body asks?

Obligations that already apply

Legacy devices are not exempt from everything. The MDR rules on post-market surveillance, market surveillance, vigilance and the registration of economic operators and devices apply to them in place of the corresponding old provisions. The earlier sell-off deadline was removed, so devices already placed on the market may continue to be made available provided they remain safe and compliant.

Where manufacturers go wrong

  • Treating a significant change as minor, which can take a device out of the transition.
  • Assuming the notified body agreement alone carries the product to the end date, while the MDR certification work slips.
  • Neglecting PMS and vigilance duties that already follow the MDR.

How PQRA helps

PQRA helps manufacturers and importers map each product to its transition position, document the evidence trail, assess whether planned changes are significant, and prepare the technical documentation and quality system for MDR conformity assessment.

Unsure whether your portfolio still sits inside the transition period? Contact PQRA for a practical discussion.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *